Introduction
============

Gastroesophageal reflux disease (GERD) is a common disorder affecting approximately 35%-40% of the adult population.[@B1],[@B2] Proton pump inhibitors (PPIs) are the most potent agents for acid suppression and standard dose (once daily) of different PPIs has been established as providing symptom relief and healing of lesions in the majority of patients.[@B3]-[@B6] Some patients require twice-daily PPI therapy, but may continue to experience GERD symptoms.[@B6],[@B7] It has been estimated that about 40% of GERD patients remain symptomatic despite treatment with PPIs.[@B8] In these patients, ongoing symptoms may be caused by persistent acid reflux due to insufficient inhibition of gastric acid production, by \"non-acid\" reflux or by other causes that can be misinterpreted as GERD.[@B9]-[@B12]

In patients with persistent GERD symptoms despite acid suppression, current management algorithms propose pH monitoring under PPIs.[@B13] However, recent studies challenged this approach showing that ambulatory pH monitoring has a low likelihood to be positive in this setting.[@B14],[@B15] The recently developed combined impedance-pH technology represents a better tool under these circumstances because it detects reflux of all types.[@B10] Impedance monitoring has the ability to detect reflux episodes independent of the pH of the refluxate and concomitant pH recording determine their acidity classifying them as acidic or non-acidic. As non-acid reflux is considered a putative cause of ongoing symptoms despite PPI therapy, combined impedance-pH monitoring seems to be the best strategy for evaluation of persistent reflux. It provides the same information as traditional pH monitoring and adds to it relevant information on the prevalence of non-acid reflux and its relation to refractory GERD symptoms.

The aim of our study was to evaluate the added yield of impedance-pH monitoring compared with conventional pH-metry in patients with persistent GERD symptoms on PPI in clinical practice.

Materials and Methods
=====================

Study Population
----------------

We analyzed 24 hour combined impedance-pH studies in patients who experienced persistent GERD-related symptoms while on PPI therapy. In addition, the daily dose of PPI (standard or double dose) and the presence of typical and atypical symptoms were analyzed in all patients. Heartburn, regurgitation and chest pain were considered typical symptoms, whereas pulmonary and ear, nose and throat (ENT) symptoms were included in atypical symptoms. All patients had a normal upper endoscopy. The study protocol was approved by the Attikon University General Hospital Institutional Review Board.

Ambulatory Impedance-pH Monitoring
----------------------------------

A 6-channel impedance catheter (outer diameter 2.3 mm) with attached pH recording at 5 cm above the manometrically localized lower esophageal sphincter was used. Before each study, the catheter was calibrated in buffer solutions of pH 7 and 4. For intraluminal impedance, the catheter enabled recordings from 6 segments, each recording segment being 2 cm. The recording segments were located at 2-4, 4-6, 8-10, 10-12, 14-16 and 17-19 cm above the manometrically localized LES. The pH and impedance signals were stored in a digital system (Omega, MMS, Enschede, The Nederlands) using a sample frequency of 50 Hz.[@B16]

Study Protocol
--------------

All patients underwent an upper endoscopy, followed by stationary esophageal manometry. Ambulatory 24 hour esophageal impedance-pH was performed on one of the next 7 days. Patients were required to be fasting for at least 6 hours before the procedure. Treatment with PPI was continued; all other drugs potentially affecting gastrointestinal motility and gastrointestinal secretion were discontinued at least 1 week prior to the study.

Data collection device, worn in a belt on the patient\'s waist, was connected to the catheter that had been introduced via nostril. Patients returned to their home and were instructed to continue their daily activities during the 24 hour measurement period. They were also asked to record a timetable of their meals and of time spending in upright and supine position on a diary card. Moreover, the occurrence of any symptom was recorded on patients\' diary card.

Data Analysis
-------------

Combined impedance-pH data collected included any type of reflux episodes. For the analysis, the periods of meal consumption were marked and excluded. Reflux events were identified based on previously described criteria and classified as acidic or non-acidic using a threshold of pH = 4.[@B9],[@B10] The symptom index (SI) was calculated for each patient in relation to acid and non-acid reflux episodes. A symptom was considered to be associated with reflux if it was preceded within 2 minutes by a reflux episode.[@B17] A positive SI was defined if \> 50% of the symptoms were associated with reflux.[@B18] Impedance-pH monitoring was considered pathological when a positive SI was present.

Statistical Methods
-------------------

Values are expressed as mean ± SD. Statistical analysis was performed by Student\'s *t* test or Chi-square testing wherever appropriate. *P*-value \< 0.050 was were considered to be significant.

Results
=======

Patient Characteristics
-----------------------

Seventy-one patients (31 men; mean age, 49.1 ± 15.5 years) with refractory reflux symptoms underwent a 24 hour combined impedance-pH monitoring under PPI therapy. Forty-two (59%) patients were treated with standard PPI dose and 29 (41%) with double PPI dose. Fifty-four (76%) patients had typical symptoms, while 35 (49%) patients had atypical symptoms.

Impedance-pH Monitoring
-----------------------

Forty-four (62%) patients reported symptoms during the 24 hour impedance-pH study; 30 patients were on standard and 14 on double PPI dose. Heartburn (34%) was the most common symptom reported, following by ENT and regurgitation (19%, respectively) while chest pain and pulmonary symptoms were reported by 14% of patients.

Standard vs Double Proton Pump Inhibitor Dose
---------------------------------------------

The proportion of patients reporting symptoms were higher in those on standard PPI compared to those on double dose (30/42 vs 14/29, *P* = 0.048). The age and sex were similar between patients on standard and on double PPI dose ([Table 1](#T1){ref-type="table"}). Among symptoms, regurgitation and pulmonary symptoms were reported more frequent by patients on once PPI daily, although the difference was not statistically significant. The percentage time of a pH \< 4 was similar in patients on standard compared to those on double PPI dose (5.5 ± 9.1 vs 4.3 ± 7.6, respectively). There was no statistically significant difference in the mean number of total reflux episodes that occurred during the study (41.3 ± 20.0 on standard dose vs 33.6 ± 18.9 on double dose, *P* = 0.220) and in the mean number of acid reflux episodes (14.3 ± 13.7 on standard dose vs 11.1 ± 8.4 on double dose, *P* = 0.416), as well.

Symptom Index Analysis
----------------------

From 44 patients, a positive SI for at least 1 of patients\' symptom was found in 21 (48%) patients. Eleven (52%) patients had a positive SI for 1 symptom, 8 (38%) patients for 2 and 2 patients (10%) for 3 symptoms. The PPI medication dose was similar between patients with and without positive SI ([Table 2](#T2){ref-type="table"}). Heartburn was the most prevalent symptom associated with reflux episodes, followed by regurgitation and ENT symptoms ([Table 2](#T2){ref-type="table"}). Regarding the frequency of reported symptoms in patients with or without positive SI, there was no statistically significant difference between typical and atypical symptoms as a whole and among any of the individual symptoms.

Of the 21 patients with an overall positive SI, 8 (18.2%) had a positive SI for acid reflux, 9 (20.5%) for non-acid reflux and 4 (9.1%) for mixed reflux ([Figure](#F1){ref-type="fig"}). Thus, addition of impedance allowed association between reflux and symptoms in 20.5% of patients who would have been missed by a pH study alone. Evidence consistent with acid reflux as a cause of symptoms was found in 27.3% of patients, whereas a temporal association between non-acid reflux and symptoms was present in 29.6% of patients. As indicated in [Table 3](#T3){ref-type="table"}, heartburn was the most prevalent symptom associated with acid reflux, whereas regurgitation and ENT symptoms were associated with non-acid reflux.

Discussion
==========

In patients with GERD symptoms refractory to PPI therapy, 24 hour pH testing is still considered the gold standard method to diagnose reflux.[@B13] However, recent studies challenged this approach showing that ambulatory pH monitoring in patients refractory to PPI therapy was most likely to be normal.[@B14],[@B15] Combined impedance-pH monitoring has recently received worldwide interest because of its ability to detect not only acid but also all types of reflux. As the main concern in patients with refractory symptoms to PPI is whether or not their symptoms are brought about by reflux, we used SI as the method that can establish a correlation between reflux and symptoms.

Our results showed that 48% of patients on PPI therapy had a positive SI for all types of reflux. A positive SI for acid reflux was found in only 27.3% of these patients. In our population, non-acid reflux was considered as the cause of symptoms in 20.5% of patients. Thus, before the advent of combined impedance- pH, this proportion of patients would have been identified as negative for GERD and represents the increased diagnostic yield of this technique compared with pH study alone. Our results are similar to a multicenter study of 168 refractory GERD patients, in which a positive SI for non-acid reflux was found in 37%.[@B11] A French-Belgian cohort study also revealed that the addition of impedance resulted in a considerable overall diagnostic gain of 16.7% in patients on PPI.[@B12] In addition, a recent study showed that 39% of patients on double daily PPI therapy had a positive SI for non-acid reflux and would have been misdiagnosed by a pH-alone study.[@B19] The combination of conventional pH monitoring with impedance was also helpful in identifying non-erosive reflux disease patients off the medication who had a positive symptom association for non-acid reflux. Without impedance addition, this subgroup of patients would have been labelled as having functional heartburn.[@B20] In a recently published study, Blonski et al[@B21] underlined the clinical importance of non-acid reflux showing that the maximal rate of reflux episodes was the same whether patients were taking medication or not.

Heartburn has traditionally been accepted as the most frequent acid-mediated symptom, and we indeed found that heart-burn was the most prevalent symptom associated with acid reflux. Regurgitation and ENT symptoms were the most common manifestations in patients with non-acid reflux. In the literature there was conflicting results regarding regurgitation; Zerbib et al[@B12] reported a positive association of regurgitation and non-acid reflux, while Kline et al[@B22] found that regurgitation accounted for 64% of symptoms in the acid-reflux group of patients. For ENT symptoms, it is widely accepted that it is unlikely to related with acid reflux.[@B23] Non-acid reflux triggering ENT symptoms is a concept that has gained interest and our results support the hypothesis that non-acid reflux could be the cause of ENT symptoms. Although our finding is very promising, we should keep in mind that the cause and effect relationship between atypical symptoms and reflux is difficult to be established. Thus, a study including more patients should have to confirm our results, as only a minority of our patients had ENT symptoms.

Once GERD has been established as a diagnosis, the next step will be to determine the response to various therapies for the patient. In patients with pathological acid exposure, a shift to a different PPI, an addition of a nighttime histamine-2 receptor antagonist or increase of PPI dose could yield a better response rate.[@B24],[@B25] In patients with non-acid or mixed reflux potential therapies would include medical therapies, such as baclofen, endoscopic therapy and surgical treatment.

Our study showed that 52% of patients reporting symptoms during the impedance-pH monitoring did not have evidence of an association of GERD-like symptoms with any type of reflux events. This information has clinical importance because this finding indicates that other causes, such as functional disorders of the esophagus or hypersensitivity to different stimuli, should be investigated. Our results are similar to previously published studies; a proportion of patients (ranged from 19% to 58%) who experienced symptoms during the study day had no evidence consistent with reflux as a cause of these symptoms.[@B12],[@B19]-[@B22]

A limitation of our study is the fact that our study population was a mixed cohort regarding medication use, with 59% on single dose of PPI. Thus, someone can argue that these patients may not represent the standard patient who should undergo further investigation with 24 hour impedance-pH monitoring. However, population of patients included in the study is representative of every day patients referred to our unit with symptoms presumed due to GERD.

In conclusion, our study showed that combined impedance-pH monitoring significantly increased the diagnostic yield of persistent pathological reflux compared to pH alone in GERD patients refractory to PPI therapy. With SI analysis, 20.5% of patients received a diagnosis that could not have been achieved with pH testing alone.
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Reflux Parameters and Symptoms of Symptomatic Patients on Standard and on Double Proton Pump Inhibitor Dose
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PPI, proton pump inhibitor; ENT, ear, nose and throat.
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Symptom-Reflux Association in 44 Symptomatic Patients on Proton Pump Inhibitor
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